Cyndi Green has been managing director at Connecticut Innovations since joining in early 2020. In 2019, Cyndi retired from Pfizer in NYC, where she was head of Business Development Search and Evaluation for anti-infectives and vaccines. Her technical leadership at Pfizer led to the formation of Pfizer/GSK spinout ViiV Healthcare, as well as the acquisitions of an anti-infective franchise from AstraZeneca and vaccine portfolios from Baxter and GlaxoSmithKline. Prior to Pfizer, she held various scientific and business positions at CuraGen, and her expertise spans the spectrum of drug development in preclinical to marketed assets, technologies, diagnostics and research platforms.
Cyndi is on the board of directors of CytoVeris, CaroGen, Thetis and BioCT and led CI portfolio investments in Enrich Therapeutics, Dugri, Oova and Aztek Bio. In addition to support of the CI portfolio, Cyndi mentors and provides consultant expertise for a variety of organizations, including ABCT, eLabNYC, Springboard Enterprises and Endless Frontier Labs.
Cyndi has a doctorate in molecular biology from SUNY Buffalo, did her postdoctoral work at Yale University, and received an MBA from Rensselaer Polytechnic Institute.